新型血管紧张肽受体拮抗药依普罗沙坦  

Eprosartan,a new angiotensin Ⅱ receptor antagonist

作　　者：黄震华[1] 

机构地区：[1]上海交通大学医学院附属第九人民医院心血管病研究室,上海200011

出　　处：《中国新药与临床杂志》2008年第8期612-615,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：依普罗沙坦是一个新型、高选择性血管紧张肽Ⅱ受体1拮抗药,尚具有改善血管内皮功能、延迟动脉粥样硬化、抗炎症等作用。依普罗沙坦不经CYP450系统代谢,故很少发生药物-药物相互作用。在降压治疗同时,依普罗沙坦尚有减少心脑血管事件发生率的作用。Eprosartan is a new highly selective angiotensin Ⅱ receptor 1 antagonist. It has the effects of improving endothelial function, delaying atherosclerosis process and anti-inflammation. Metabolism of eprosartan does not require the cytochrome P450 enzyme system and has less drug-drug interactions. Eprosartan also could reduce the occurrence of cardiovascular and celebrovascular events in the treatment of hypertension.

关 键 词：肾素-血管紧张肽系统 高血压 抗高血压药 依普罗沙坦 

分 类 号：R972.4[医药卫生—药品]